1. Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data

3. CV Outcomes Trials of Glucose-Lowering Drugs in T2DM

4. PROactive: Study Design

5. PROactive: Primary and Secondary Outcomes

6. PROactive: HF and Bladder Cancer

7. DPP-4 Inhibitor CV Outcomes Trials: Study Designs

8. DPP-4 Inhibitor CV Outcomes Trials: Primary Endpoint

9. DPP-4 Inhibitor CV Outcomes Trials: Hospitalization for HF

10. Future DPP-4 CV Outcomes Trials in T2DM

11. ELIXA: Study Design

12. ELIXA: Primary Outcome -- CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for UA

13. ELIXA: HF Hospitalization

14. LEADER: Study Design

15. LEADER: Top-Line Results

16. Timeline of Future GLP-1 RA CV Outcome Trials

17. Reducing Glucose Reabsorption via Inhibition of the SGLT2 Pathway

18. EMPA-REG OUTCOME: Study Design

19. EMPA-REG OUTCOME: Key Inclusion and Exclusion Criteria

20. EMPA-REG OUTCOME: Baseline CV Demographics

21. EMPA-REG OUTCOME: CV Medication Use

22. EMPA-REG OUTCOME: Glucose-Lowering Medications

23. EMPA-REG OUTCOME: T2DM in the Study Population

24. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on the Primary Composite Outcome

25. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on Individual MACE Endpoints

26. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on All-Cause Mortality

27. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on HF Hospitalization

28. EMPA-REG OUTCOME: HF Hospitalization or Death From HF

29. EMPA-REG OUTCOME: HF Hospitalization in Patients With vs Without HF at Baseline

30. EMPA-REG OUTCOME: Potential Mechanism

31. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on CV Death

32. EMPA-REG OUTCOME: Patient Profile

33. IRIS: Pioglitazone in Patients With Insulin Resistance

34. Ongoing SGLT2 Inhibitor CV Outcomes Trials

35. Abbreviations

36. Abbreviations (cont)